Navigation Links
StockCall Research on Boston Scientific and Medtronic: Focus on Paroxysmal Atrial Fibrillation
Date:1/22/2013

LONDON, January 22, 2013 /PRNewswire/ --

The medical appliances and equipment industry faced its fair share of challenges during the recession, as procedural volume in some cases was reduced due to the economic situation in the U.S. and Europe. Analysts from our services research team completed in-depth analysis on Boston Scientific Corporation (NYSE: BSX) and Medtronic Inc. (NYSE: MDT). These free reports are available at

http://www.stockcall.com/registration    

Competition also crimped margins for several companies, leading to lower sales and profits. However, with the recession in the rear view mirror, the outlook for the industry and companies such as Boston Scientific and Medtronic is positive. Now that companies have been afforded some breathing room, they are focusing their attentions on bringing new products to market and growing their international footprint. Download the free report on Scientific by signing up now at

http://www.StockCall.com/BSX012213.pdf

Both Boston Scientific and Medtronic [Free Report on MDT][1] have been looking to new products to grow their top- and bottom-lines, and both have recently been involved with paroxysmal atrial fibrillation. Atrial fibrillation affects around 15 million people globally, and can cause serious health problems such as strokes and heart failure.

In the case of Boston Scientific, the company newly announced that the first patient has been treated in its ZERO AF clinical trial. The results of the trial are anticipated to be used to back up an FDA regulatory submission for a paroxysmal atrial fibrillation indication.

Medtronic has also been busy, recently stating that the FDA has cleared the FlexCath Advance (TM) Steerable Sheath, an improvement to the Arctic Front Advance (TM) Cryoballon System. The new sheath will make it easier to reach inferior veins of the heart when delivering and positioning the cryoballoon catheter in the left atrium to treat paroxysmal atrial fibrillation.

Footer:

  1. Medtronic Inc. Technical Analysis [ http://www.StockCall.com/MedtronicInc012213.pdf ]

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

http://www.stockcall.com  


'/>"/>
SOURCE StockCall.com
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Drug Discovery and Development Market in Asia - Partnerships Between MNCs and Asian Academic Institutions and Healthcare Research Organizations are Driving R&D Innovation
2. Russian Government Starts Using Scopus for National Research Assessment
3. Breakthrough Research Could Create Sea Change in Global HIV Diagnosis: New Handheld Mobile Device Performs Laboratory-Quality HIV Testing
4. US Vitamin injections Posts New Research Involving B Vitamin Deficiency
5. Maximizing the Effectiveness of Market Research Groups through Outsourcing and Automation
6. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
7. BodyMedia Collaborates on Federal Health Research Study
8. Genomic Research Service Provider DNA Link Purchases 10 Ion Proton Sequencers
9. Fred Hutchinson Cancer Research Center Partners With GlaxoSmithKline to Develop Muscular Dystrophy Therapeutics
10. Seahorse Bioscience Announces Asia Mito 2012 Travel Award Winners Advancing Cell Metabolism Research
11. German Cancer Research Center Selects Contur ELN from Accelrys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... MD (PRWEB) , ... June 24, 2016 , ... ... protocols for human induced pluripotent stem (iPS) cells and other difficult to transfect ... G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is a ...
Breaking Medicine News(10 mins):